Strand Life Sciences: Financial Breakdown
Decoding financial health metrics of Strand Life Sciences
- Total Revenue₹97.1 Cr10%
Prev. FY
- Total Expenses₹102.0 Cr25%
Prev. FY
- Profit After Tax₹-3.7 Cr-128%
Prev. FY
- Total Assets₹134.2 Cr10%
Prev. FY
- Net Profit Margin-3.8%-125%
Prev. FY
FAQs on Financials of Strand Life Sciences
No. In FY24, Strand Life Sciences reported a net loss of ₹3.7 Cr, so it was not profitable.
Strand Life Sciences's revenue grew 10.7% year-on-year, from ₹87.7 Cr in FY23 to ₹97.1 Cr in FY24.
Strand Life Sciences's estimated EBITDA for FY24 was ₹-1.6 Cr, derived from its profit before tax, finance costs, and depreciation & amortisation.
In FY24, Strand Life Sciences posted revenue of ₹97.1 Cr (up 10.7% YoY) and a net loss of ₹3.7 Cr. Explore the full financials of Strand Life Sciences here...
Disclaimer
Inc42 Datalabs consolidates intelligence from public records, statutory filings, proprietary research, and vetted third‑party datasets. All information is provided as is—please run your own checks before acting on it. Inc42 Datalabs bears no responsibility for decisions or outcomes based on this data.
Quick Links

